SCHEMBL8167142

SCHEMBL8167142

Cc1ccc(C(=O)NNC(C)(C)C)cc1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.69
GAA P10253 2/20 0.69
HDAC1 Q13547 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
TDP1 Q9NUW8 2/20 0.53
RAB9A P51151 7/20 0.52
NPC1 O15118 6/20 0.52
PTGS2 P35354 2/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CCR6 P51684 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9247147 0.84 SRD5A2 (0.50) ALDH1A1GAAHDAC1RAB9ANPC1
SCHEMBL7103221 0.83 ALDH1A1 (1.00) ALDH1A1GAAHDAC1HDAC6TDP1
SCHEMBL7038963 0.82 POLB (0.68) ALDH1A1GAAHDAC1TDP1RAB9A
SCHEMBL3137092 0.82 SMN1; SMN2 (0.62) ALDH1A1GAAHDAC1HDAC6RAB9A
SCHEMBL8173747 0.80 ALDH1A1 (0.58) ALDH1A1GAAHDAC1HDAC6TDP1
Toluene SCHEMBL8172415 0.80 SMN1; SMN2 (0.51) ALDH1A1GAATDP1RAB9ANPC1
SCHEMBL1526586 0.80 CYP2C19 (0.45) ALDH1A1GAASMN1; SMN2KDM4E
SCHEMBL24590217 0.79 MAPT (0.70) ALDH1A1GAAHDAC1TDP1RAB9A
SCHEMBL7038117 0.79 ALDH1A1 (0.60) ALDH1A1GAATDP1RAB9ANPC1
SCHEMBL2264435 0.79 ALDH1A1 (0.61) ALDH1A1GAAHDAC1HDAC6RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174619-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2017-06-22 US claimed
WO-2015153516-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2015-10-08 WO claimed
US-11731934-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-22 US disclosed
US-11731934-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-08-22 US disclosed
US-20210009509-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2021-01-14 US disclosed
US-20210009509-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2021-01-14 US disclosed
US-10807944-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2020-10-20 US disclosed
US-10807944-B2 HDAC inhibitor compounds and methods of treatment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2020-10-20 US disclosed
US-20170174619-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2017-06-22 US disclosed
US-20170174619-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2017-06-22 US disclosed
WO-2015153516-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2015-10-08 WO disclosed
US-5424333-A Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines ROHM AND HAAS COMPANY (US) 1995-06-13 US disclosed
US-5354762-A Insecticides ROHM AND HAAS COMPANY (US) 1994-10-11 US disclosed
EP-0361645-B1 ORGANIC HYDRAZINE DERIVATIVES FOR PHARMACEUTICAL USE ROHM AND HAAS COMPANY (US) 1993-09-29 EP disclosed
EP-0261755-B1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVES OF N'-SUBSTITUTED-N,N'-DIACYLHYDRAZINES ROHM AND HAAS COMPANY (US) 1992-12-16 EP disclosed
US-5117057-A Insecticidal N' substituted-N-N'-disubstituted-hydrazines ROHM AND HAAS COMPANY (US) 1992-05-26 US disclosed
EP-0253468-B1 SIX-MEMBERED HETEROCYCLIC DERIVATIVES OF N'SUBSTITUTED-N,N'-DIACYLHYDRAZINES ROHM AND HAAS COMPANY (US) 1991-11-06 EP disclosed
EP-0361645-A2 Organic hydrazine derivatives for pharmaceutical use ROHM AND HAAS COMPANY (US) 1990-04-04 EP disclosed
EP-0261755-A2 Five-membered heterocyclic derivatives of N'-substituted-N,N'-Diacylhydrazines ROHM AND HAAS COMPANY (US) 1988-03-30 EP disclosed
EP-0253468-A2 Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines ROHM AND HAAS COMPANY (US) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174619-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT HDAC4, HDAC1, HDAC5 ALDH1A1 168/4885GAA 436/4885HDAC1 2/4885
US-11731934-B2 HDAC inhibitor compounds and methods of treatment HDAC4, HDAC1, HDAC5 ALDH1A1 168/4885GAA 436/4885HDAC1 2/4885
US-20210009509-A1 HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT HDAC4, HDAC1, HDAC5 ALDH1A1 168/4885GAA 436/4885HDAC1 2/4885
US-10807944-B2 HDAC inhibitor compounds and methods of treatment HDAC4, HDAC1, HDAC5 ALDH1A1 168/4885GAA 436/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.